相关实验视频

Updated: Jun 5, 2025

Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation

Isolation, Characterization, and Purification of Macrophages from Tissues Affected by Obesity-related Inflammation

Published on: April 3, 2017

在实验室中,用西塔利普丁治疗会使巨细胞中的M2表型恶化

Laura Quadros-Pereira¹, José Arimatéa de Oliveira Nery-Neto², Eloisa Martins Da Silva³

¹Mucosal Health and Immunology Laboratory (MHIL), Center for Natural and Human Science, Federal University of ABC, Santo André, São Paulo, Brazil.

International immunopharmacology

|December 11, 2024

概括

用于糖尿病的西塔格利普丁在体外加重M2巨细胞表型. 这涉及到改变线粒体功能和减少细胞形成,影响免疫反应.

科学领域:

免疫学免疫学免疫学
药理学药理学是指药理学的学科.
细胞生物学细胞生物学

背景情况:

巨细胞 (MØ) 是关键的免疫细胞,参与恒温和炎症性疾病.
西塔格利普丁是一种DPP-4抑制剂,可以治疗II型糖尿病和肥胖症,并已显示出抗炎作用的潜力.
西塔利普丁调节免疫反应的机制,特别是MØ激活和功能,仍然不清楚.

研究的目的:

为了研究和描述在实验室中西塔利普丁对巨细胞两极分化的影响.
阐明西塔利普丁如何影响MØ表型,线粒体动态和细胞容量.

主要方法:

来自骨髓的MØ被分化并分化为M1或M2表型.
细胞在极化过程中接受了西塔利普丁治疗,并评估了M1/M2标记物,DPP-4,隐素受体,线粒体功能和细胞.

主要成果:

西塔格利普丁治疗加剧了M2巨细胞表型,由增加的CD206和ARG1表达和减少的TNF-α表明.
西塔格利普丁诱导的M2 MØ表现出改变的线粒体动力学,包括减少的膜潜力和ROS产量.
这些M2 MØ显示了细胞能力受损和与线粒体融合相关的基因表达改变.

结论:

实验室内西塔格利普丁治疗促进了M2巨的形状.
该药物干扰线粒体功能,并降低M2巨细胞的细胞活性.
这些发现表明,西塔利普丁可能通过MØ极化调节影响免疫反应.

关键词:

在DPP-4中使用.在GIPR中,GIPR是GIPR的代表.这是一个GLP-1RR.巨细胞是一个巨细胞.西塔格利普丁是如何使用的

更多相关视频

Depletion and Reconstitution of Macrophages in Mice

Depletion and Reconstitution of Macrophages in Mice

Published on: August 1, 2012

Investigation of Macrophage Polarization Using Bone Marrow Derived Macrophages

Investigation of Macrophage Polarization Using Bone Marrow Derived Macrophages

Published on: June 23, 2013

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...